share_log

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K: Current report

Elevai Labs | 8-K:重大事件
美股SEC公告 ·  2024/11/14 00:25

Moomoo AI 已提取核心訊息

Elevai Labs has received a conditional extension from Nasdaq to maintain its listing, following its failure to meet the minimum $1.00 bid price requirement since March 6, 2024. The company must complete a reverse stock split by December 26, 2024, and demonstrate compliance with the bid price rule by January 9, 2025.The company's compliance plan, presented at the October 22 Nasdaq hearing, includes raising $8 million through a public offering, obtaining shareholder approval for a reverse stock split, and completing a tender offer to exchange common stock for non-trading preferred stock by December 16, 2024.During the extension period until January 9, 2025, Elevai Labs must promptly notify Nasdaq of any significant events affecting its compliance status. The company has until November 22, 2024, to request a review of the Panel's determination by the Nasdaq Listing and Hearing Review Council, which would require a $15,000 review fee.
Elevai Labs has received a conditional extension from Nasdaq to maintain its listing, following its failure to meet the minimum $1.00 bid price requirement since March 6, 2024. The company must complete a reverse stock split by December 26, 2024, and demonstrate compliance with the bid price rule by January 9, 2025.The company's compliance plan, presented at the October 22 Nasdaq hearing, includes raising $8 million through a public offering, obtaining shareholder approval for a reverse stock split, and completing a tender offer to exchange common stock for non-trading preferred stock by December 16, 2024.During the extension period until January 9, 2025, Elevai Labs must promptly notify Nasdaq of any significant events affecting its compliance status. The company has until November 22, 2024, to request a review of the Panel's determination by the Nasdaq Listing and Hearing Review Council, which would require a $15,000 review fee.
Elevai Labs已從納斯達克獲得了有條件的延長,以維持其上市資格,因爲自2024年3月6日以來未能滿足最低1.00美元的買盤價格要求。該公司必須在2024年12月26日前完成反向股票拆分,並在2025年1月9日前證明遵守買盤價格規則。該公司在2023年10月22日的納斯達克聽證會上提出的合規計劃包括通過公開募股籌集800萬的資金,獲得股東對反向股票拆分的批准,並在2024年12月16日前完成以普通股換取非交易優先股的要約。在延長期間直到2025年1月9日,Elevai Labs必須及時通知納斯達克任何影響其合規狀態的重要事件。該公司必須在2024年11月22日之前請求納斯達克上市與聽證審查委員會對小組決定的審查,此請求需要支付15,000美元的審查費。
Elevai Labs已從納斯達克獲得了有條件的延長,以維持其上市資格,因爲自2024年3月6日以來未能滿足最低1.00美元的買盤價格要求。該公司必須在2024年12月26日前完成反向股票拆分,並在2025年1月9日前證明遵守買盤價格規則。該公司在2023年10月22日的納斯達克聽證會上提出的合規計劃包括通過公開募股籌集800萬的資金,獲得股東對反向股票拆分的批准,並在2024年12月16日前完成以普通股換取非交易優先股的要約。在延長期間直到2025年1月9日,Elevai Labs必須及時通知納斯達克任何影響其合規狀態的重要事件。該公司必須在2024年11月22日之前請求納斯達克上市與聽證審查委員會對小組決定的審查,此請求需要支付15,000美元的審查費。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息